Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone

E-ISSN： 2212-3970|1|3|347-355

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.1, Iss.3, 2006-11, pp. : 347-355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation

International Journal of Oncology, Vol. 47, Iss. 1, 2015-01 ,pp. : 253-261

Spandidos Publications

Access to resources Recommend Favorite

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 995-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Abl tyrosine protein kinase

By Laneuville P.

Seminars in Immunology, Vol. 7, Iss. 4, 1995-04 ,pp. : 255-266

Academic Press

Access to resources Recommend Favorite

Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor

By Kimura Shinya Niwa Tomoko Hirabayashi Kazuko Maekawa Taira

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 55-61

Springer Publishing Company

Access to resources Recommend Favorite

Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor

By Kimura Shinya Niwa Tomoko Hirabayashi Kazuko Maekawa Taira

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 55-61

Springer Publishing Company

Access to resources Recommend Favorite